Nordicus Partners Corp (NORD)

[e-ore]

ASNB - The powerwand is coated with ASNB's patented Chronoflex C. Note my highlights below:

The POWERWAND can be used both for the administration of fluids/medications and for withdrawing blood for diagnostic tests. It is the first and only power-injectable peripheral IV (PIV) catheter capable of delivering continuous IV therapy for the patient’s entire length of hospital stay. The device may be left in place for up to 29 days per its FDA clearance. It is also designed to be an integral part of any program to reduce central-line associated bloodstream infections (CLABSI)

Infection. 2013 Jul 3. [Epub ahead of print]
Costs and prolonged length of stay of central venous catheter-associated bloodstream infections (CVC BSI): a matched prospective cohort study.
Leistner R, Hirsemann E, Bloch A, Gastmeier P, Geffers C.
Source
Institute of Hygiene and Environmental Medicine, National Reference Center for the Surveillance of Nosocomial Infections, Charité, University Medicine Berlin, Hindenburgdamm 27, 12203, Berlin, Germany, [e-mail].
Abstract
PURPOSE:
Central venous catheter-associated bloodstream infections (CVC BSI) are a common and serious complication among critically ill patients on intensive care units (ICUs), but also result in a financial burden for the health care system. Our aim was to determine the additional costs and length of stay (LOS) of patients with ICU-acquired CVC BSI.
METHODS:
We used the surveillance method of the German nosocomial infection surveillance system (Krankenhaus Infections Surveillance System, KISS) to find cases of CVC BSI. The associated costs of CVC BSI were estimated as true costs generated within our hospital. We used a matched cohort design, comparing patients with CVC BSI and patients without BSI. The study period was from January to December 2010. Patients were matched by age, sex, and Simplified Acute Physiology Score (SAPS). The LOS in the ICU of control patients needed to be at least as long as that of CVC BSI patients before the onset of CVC BSI.
RESULTS:
We matched 40 CVC BSI patients to 40 patients without BSI. The median hospital costs for CVC BSI patients were significantly higher than for patients without BSI (60,445 <euro> vs. 35,730 <euro>; p = 0.006) and the CVC BSI patients stayed longer in the hospital than patients without CVC BSI (44 days vs. 30 days; p = 0.110). The median attributable costs per CVC BSI was 29,909 <euro> (p = 0.006) and the median attributable LOS was 7 days (p = 0.006).
CONCLUSION:
CVC BSI is associated with increased hospital costs and prolonged hospital stay. Hospital management should implement control measurements to keep the incidence of CVC BSI as low as possible.

"Greater patient satisfaction, due to extended dwell time and blood draw-ability. In a published, peer-reviewed study (JAVA, Spring 2012), patients rated their satisfaction with the device at 98.7%. By comparison, only a minority of patients (42%) reports being satisfied about their experience with other kinds of peripheral IVs."

"Finally, there is the new CMS incentive—under Medicare’s “value-based purchasing” program—to increase patient satisfaction with the inpatient experience. Hospitals showing “better than average” or “most improved” patient satisfaction are eligible for Medicare bonus payments from a pool of $850 million."

http://www.ncbi.nlm.nih.gov/pubmed/23821485